What is the 13F Pro Quality Score for KAPA?

13F Pro ranks Kairos Pharma, LTD. (KAPA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View KAPA's current score at https://13fpro.ai/research/KAPA (free sign-up required for the full ranking).

Where does 13F Pro source KAPA data?

All Kairos Pharma, LTD. fundamentals and ownership data come directly from SEC EDGAR. Kairos Pharma, LTD. files with the SEC under CIK 1962011. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is KAPA in?

Kairos Pharma, LTD. (KAPA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is KAPA research updated on 13F Pro?

KAPA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Kairos Pharma, LTD.(KAPA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 1962011 KAPA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

KAPA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Kairos Pharma, LTD. (KAPA), a Healthcare sector company. KAPA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Kairos Pharma, LTD. reports net income of $-1.7M, free cash flow of $-1.0M. Top institutional holders of KAPA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. KAPA trades on the NYSE exchange and files with the SEC under CIK 1962011. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KAPA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kairos Pharma, LTD. directly from SEC EDGAR.

Net Income

Q1 2026

$-1.7M

Free Cash Flow

Q1 2026

$-1.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-109.3% YoY

$-5.4MFY 2025

FY22 —FY23 $-1.8MFY24 $-2.6MFY25 $-5.4M

Operating Income

-137.8% YoY

$-5.6MFY 2025

FY22 —FY23 $-1.7MFY24 $-2.3MFY25 $-5.6M

EPS (Diluted)

-30.4% YoY

$-0.30FY 2025

FY22 —FY23 $-0.17FY24 $-0.23FY25 $-0.30

Total Assets

+13.4% YoY

$6.5MFY 2025

FY22 —FY23 $965.0KFY24 $5.8MFY25 $6.5M

Op. Cash Flow

+13.0% YoY

$-3.4MFY 2025

FY22 —FY23 $81.0KFY24 $-4.0MFY25 $-3.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Net Income	$-5.4M -109.3%	$-2.6M -43.7%	$-1.8M	—
Operating Income	$-5.6M -137.8%	$-2.3M -36.7%	$-1.7M	—
EPS (Diluted)	$-0.30 -30.4%	$-0.23 -35.3%	$-0.17	—
Total Assets	$6.5M +13.4%	$5.8M +497.7%	$965.0K	—
Operating Cash Flow	$-3.4M +13.0%	$-4.0M -4982.7%	$81.0K	—

AI Insight: KAPA Financial Trends

Kairos Pharma's losses deepened in Q1 2026 while revenue visibility remains absent from reported financials.

• Net income and operating income both deteriorated to –$2M in Q1 2026, doubling losses from prior quarters' –$1M run rate.

• Operating cash flow held steady at –$1M in Q1 2026, suggesting burn rate stabilized despite widened net losses.

• Equity eroded to $5M in Q1 2026, lowest level in reported history, after fluctuating between $5M–$8M across prior quarters.

⚠ No revenue line reported across any period; inability to assess commercial traction or path to profitability.

⚠ Q1 2026 marks first quarter with doubled operating losses; inflection risk if cash burn accelerates further.

AI Insight: KAPA Ratio Trends

Kairos Pharma remains deeply unprofitable with deteriorating shareholder returns; Q1 2026 ROE plunged to -124.5%, the worst on record.

• ROE collapsed to -124.5% in Q1 2026 from -86.1% in Q4 2025, signaling accelerating losses and capital destruction.

• ROA deteriorated to negative (Q4 2025: -83.5%; Q1 2026 data sparse) across all recent quarters, indicating persistent operational losses.

• ROIC remained deeply negative throughout 2025 (range: -74.9% to -97.1%), destroying invested capital consistently.

⚠ Q1 2026 ROE worse than any prior period shown; assess whether this reflects seasonality, clinical setbacks, or structural profitability issues.

⚠ OpMargin, NPM, and D/E data absent throughout—limits visibility on cost structure, liquidity, and leverage trajectory.

Get alerted when KAPA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Kairos Pharma, LTD. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of KAPA

VANGUARD CAPITAL MANAGEMENT LLC
$129.6K231,878 sh
GEODE CAPITAL MANAGEMENT, LLC
$62.2K111,290 sh
VANGUARD FIDUCIARY TRUST CO
$35.7K63,884 sh
SevenBridge Financial Group, LLC
$30.3K44,286 sh
Aptus Capital Advisors, LLC
$24.8K44,286 sh
TWO SIGMA INVESTMENTS, LP
$22.1K39,543 sh
STATE STREET CORP
$13.5K24,100 sh
TWO SIGMA SECURITIES, LLC
$9.1K16,247 sh
Tower Research Capital LLC (TRC)
$2.2K3,962 sh
HRT FINANCIAL LP
$12.0021,575 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$129.6K	231,878
GEODE CAPITAL MANAGEMENT, LLC	$62.2K	111,290
VANGUARD FIDUCIARY TRUST CO	$35.7K	63,884
SevenBridge Financial Group, LLC	$30.3K	44,286
Aptus Capital Advisors, LLC	$24.8K	44,286
TWO SIGMA INVESTMENTS, LP	$22.1K	39,543
STATE STREET CORP	$13.5K	24,100
TWO SIGMA SECURITIES, LLC	$9.1K	16,247
Tower Research Capital LLC (TRC)	$2.2K	3,962
HRT FINANCIAL LP	$12.00	21,575

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put KAPA on your watchlist

Track score changes the day Kairos Pharma, LTD. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is KAPA a good stock to buy?

13F Pro's AI-powered analysis of Kairos Pharma, LTD. (KAPA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KAPA are available on the KAPA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own KAPA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KAPA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kairos Pharma, LTD.'s investment landscape.